2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
Dr. Misty Humphries reviews the sex specific analysis from the Disrupt PAD III Observational Study while at VIVA 2022. Because females often present with more difficult characteristics for endovascular therapy, this analysisof 1,373 patients aimed to illustrate that IVL can safely and effectively modify calcium regardless of gender. Dr. Humphries shares that despite women having smaller vessels, the complication rate was extremely low, with no significant difference in embolization or perforations when using Shockwave IVL to treat PAD.
Check out the presentation below and hear from Dr. Humphries on the importance of this ‘real-world’ data set in the treatment of heavily calcified PAD.
Read More
Topics:
Peripheral IVL
Calcified hostile access can be an exclusion criteria for endograft delivery and has been associated with both perioperative and long term morbidity and mortality…this is changing! Join the discussion between Drs Bosiers, Fazzini and Isernia and hear how IVL is changing the boundaries in their daily practice for endograft delivery by changing vessel compliance, providing excellent luminal gain and improving patient safety, simplifying the challenges raised by hostile calcified access.
Read More
Topics:
Peripheral IVL
Tune in for session 2 of Shockweek on Vascupedia as Dr. Elias Noory treats multiple highly calcified femoropopliteal lesions with IVL. During the session, our expert panel of Drs Lorenzo Patrone, Enrique Alejandre Lafont, Bella Huasen and Thanos Saratzis discuss how IVL can overcome the pitfalls of CLTI treatment by changing vessel compliance to reduce procedural complications. Dr. Noory and the panel also share pearls of wisdom on how to optimize your IVL strategy to get the best outcomes for patients and crack the calcium conundrum.
Read More
Topics:
Peripheral IVL
Shockwave partnered with Vascupedia to host a week-long virtual event with live cases and panel discussions. Session one focuses on ‘A New Approach to Tackling Calcified Disease in Large Vessels’. In the session, Dr. Elias Noory presents a live case from Bad Krozingen, Germany and is accompanied by an esteemed panel of Drs Arko, Bisdas and Coscas who discuss the role of endovascular treatment for common femoral disease.
Tune in to hear from the experts on how IVL is changing the treatment paradigm for heavily calcified CFA disease by providing a safe and effective treatment for calcified vessels. See how Dr. Noory utilizes IVL to achieve increased vessel compliance and luminal gain to enable a ‘leave-nothing-behind’ strategy.
For the full video from Day 1 click here: https://vascupedia.com/presentation/a-new-approach-to-tackling-calcified-disease-in-large-vessels-shockweek-day-1/
Read More
Topics:
Peripheral IVL
In a late-breaking clinical trial session at VIVA22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study (OS). PAD III OS represents the largest prospective ‘real-world’ evidence for the treatment of complex, heavily calcified peripheral artery disease. Building on the interim results presented at VIVA21, this larger patient data set reinforces the predictability of IVL and its ability to consistently modify calcium across vessel beds, challenging lesions, and complex patients (CLI, dialysis, and female patients). These real-world outcomes mirror the previously reported PAD III Randomized-Controlled Trial showing that IVL safely and effectively modifies challenging calcium in complex patients.
Check-out the presentation below and hear from Dr. Armstrong on the importance of the largest prospective ‘real-world’ data set in the treatment of heavily calcified PAD.
Read More
Topics:
Peripheral IVL,
Peripheral Conferences,
Peripheral Clinical Data,
Shockwave M5 & Shockwave M5+
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Female vs. Male Outcomes,
Empower CAD
Join us in Las Vegas for VIVA 2022 as we crack into late breaking data supporting IVL’s consistency in calcium modification in real-world PAD. The late breaker, presented by Dr. Ehrin Armstrong, features the final 1,373 patient cohort datafrom the Disrupt PAD III Observational Study. Following the data release, an esteemed panel will discuss IVL’s consistent outcomes from both real-world AND randomized studies. Don’t roll the dice with calcium modification and join us at VIVA2022!
Read More
Topics:
Peripheral IVL,
IVL Technology,
Peripheral Conferences,
Peripheral Clinical Data
At AMP 2022, Dr. Peter Soukas presented the largest set of real-world data on Shockwave IVL in CLI patients. These data include results from patient groups historically not included in other PAD studies, such as Rutherford 6 and dialysis patients, and patients with single or absent vessel run-off. These data show the significant reduction of stenosis post-IVL in these patients, the minimal complications and the consistent results across multiple vessel beds. In this presentation Dr. Soukas shares why these data are important for physicians who treat CLI, and how his calcium modification algorithm has changed over time with IVL.
Read More
Topics:
Peripheral IVL,
Peripheral Conferences,
Peripheral Clinical Data,
Shockwave M5 & Shockwave M5+
Calcified lesions in CLTI patients pose a number of hurdles for endovascular therapy including acute and sub-acute recoil, flow-limiting dissections and distal embolization. In this presentation from Charing Cross 2022 Dr. Thulasidasan shares how Shockwave IVL has improved his treatment for CLTI patients with low complications and increased durability. Dr. Thulasidasan walks through case examples with IVL in CLTI patients and states how the data supporting IVL backs up what he’s seeing in practice.
Read More
Topics:
Peripheral IVL,
Peripheral Conferences,
Peripheral Clinical Data
